A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Conditions

• Ovarian Cancer
• Ovarian Neoplasms

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Sacituzumab tirumotecan — DRUG
  Administered via intravenous (IV) infusion at a dose of 4mg/kg
• Bevacizumab — DRUG
  Administered via IV infusion at a dose of 15mg/kg
• Rescue Medications — DRUG
  Participants must receive prophylactic steroid mouthwash (dexamethasone or equivalent). It is recommended that participants receive the following rescue medications prior to sac-TMT infusion, per approved product label: histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent.

Study Details

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

Key Dates

First listed

Jan 6, 2026

Start date

Feb 16, 2026

Status verified

Aug 2026

Primary completion

Feb 25, 2033

Completion

Feb 25, 2033

Study Design

Enrollment

900 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Sac-TMT +/- Bevacizumab
  Participants will receive sac-TMT on days 1, 15, and 29 (q2W) of every 6-week cycle, until disease progression, prohibitive toxicity, or other protocol-defined reason for discontinuation. Participants receive optional bevacizumab at investigator's discretion on Days 1 and 22 (q3w) of every 6-week cycle, for up to 22 courses.
• Active Comparator: Standard of Care
  Participants will either receive bevacizumab q3w of every 6-week cycle for up to 22 courses until disease progression, prohibitive toxicity, or other protocol-defined reason for discontinuation of study intervention, or will be observed only and actively followed if not receiving bevacizumab.

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: Up to approximately 49 months ]

Central Contacts

• Toll Free Number
  1-888-577-8839
  [email protected]

Locations (25)

Find similar trials in Birmingham, AL

Related Studies

• Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
  Recruiting · Northwestern University · Chicago, Illinois
• Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
  Recruiting · M.D. Anderson Cancer Center · Miami, Florida
• Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
  Recruiting · Stanford University · Stanford, California
• Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland